Gene therapy offers the possibility of addressing cancer at its molecular roots by targeting disease-causing genes rather than relying solely on surgery, chemotherapy, or radiotherapy.

There has been considerable success in the construction of highly infectious amphotropic viral gene transfer vectors. Retroviral vectors possessing either the murine amphotropic envelope glycoprotein ...

SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the ...

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers AvenCell selected ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...

Charles River Laboratories International, Inc. CRL and Captain T Cell, a spinoff from Max Delbrück Center in Germany, entered into an agreement on plasmid DNA and retrovirus vector production program.

Viral contamination is an inherent risk during the manufacture of biopharmaceutical products. Whether introduced initially from raw materials or later through specific manufacturing operations, ...

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell’s deep expertise and track record. LONDON & NEW ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN ...